Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pau Montesinos Fernández"'
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Externí odkaz:
https://doaj.org/article/7621093bf9e0435ab51db257b2df8022
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, José Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Natalia Alonso Vence, Laura Bao Pérez, Roi Ferreiro Ferro, Manuel Albors Ferreiro, Aitor Abuín Blanco, Emilia Fontanes Trabazo, Claudio Cerchione, Giovanni Martinnelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Acute Myeloid Leukemia (AML) is a heterogeneous neoplasm characterized by cytogenetic and molecular alterations that drive patient prognosis. Currently established risk stratification guidelines show a moderate predictive accuracy, and newer tools th
Externí odkaz:
https://doaj.org/article/0c2126a43e2b4b08bd36aea5a3a142eb
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
BackgroundFLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Cu
Externí odkaz:
https://doaj.org/article/cbe01aa7d0234032abc58f5a46490841
Autor:
Aitor Abuin Blanco, Ángeles Bendaña López, Adrián Mosquera Orgueira, Giovanni Martinelli, Andrés Peleteiro Raíndo, Laura Bao Pérez, Natalia Alonso Vence, José Luis Bello López, Marta Sonia González Pérez, Roi Ferreiro Ferro, Miguel Cid López, José Ángel Díaz Arias, Pau Montesinos Fernández, Claudio Cerchione, Paula Melero Valentín, Beatriz Antelo Rodríguez, Manuel Mateo Pérez Encinas
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
PLoS ONE
PLoS ONE
Background FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.